<DOC>
	<DOCNO>NCT00601965</DOCNO>
	<brief_summary>This study ass whether add cognitive behavioral therapy antidepressant escitalopram effective reduce anxiety old adult generalize anxiety disorder .</brief_summary>
	<brief_title>Antidepressant Treatment Plus Cognitive Behavioral Therapy Generalized Anxiety Disorder Older Adults</brief_title>
	<detailed_description>Generalized anxiety disorder ( GAD ) affect nearly 6.8 million adult United States . GAD diagnose person spends least 6 month excessively worry everyday problem point carry normal life become difficult . People GAD face day intense anxiety tension unable alleviate worry . Physical symptom GAD include muscle ache , nausea , sweating , exhaustion , irritability , frequent urination , shake , hot flash . People GAD often experience anxiety disorder , depression , substance abuse , worsen symptom GAD . This make early appropriate treatment GAD important . Current treatment GAD include medication and/or type psychotherapy . This study ass whether add cognitive behavioral therapy ( CBT ) antidepressant escitalopram effective reduce anxiety old adult GAD . Participation double-blind study last 13 month . Participants ask stop current treatment anxiety depression duration study . Participants begin take one pill medication escitalopram daily 12 week . Dosage increase two pill day symptom improve within 4 week . After 12 week , participant continue take escitalopram additional 16 week . In addition , participant randomly assign receive 16 weekly session CBT , last 1 hour . CBT session involve learn relaxation technique skill manage anxiety complete 30-minute at-home practice assignment day . A family member accompany participant first four CBT session . All participant ask provide information close contact , interview baseline , Month 3 , Month 7 participant 's anxiety affect relationship . After 16-week period , participant randomly assign receive either continue escitalopram placebo additional 28 week . Participants assign placebo gradually tapered escitalopram 6-week period . Participants receive CBT receive three session . Throughout study , participant ask complete various assessment , include questionnaire , memory thinking test , attention evaluation . Blood sample take Weeks 2 8 , saliva sample take baseline Weeks 12 , 28 , 56 .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Principal ( i.e. , severe press problem ) coprincipal current diagnosis generalize anxiety disorder Pretreatment score least 17 Hamilton Anxiety Rating Scale Principal diagnosis GAD Clinically judge psychiatrically unstable participate study Cognitive impairment dementia Alcohol substance use disorder within 6 month prior study entry Lifetime diagnosis schizophrenia , schizoaffective disorder , delusional disorder , bipolar disorder Serious , unstable , terminal medical condition would compromise study participation preclude use escitalopram , determine review medical record Use psychotropics could safely taper discontinue least 2 week prior study entry Use depot neuroleptic within 6 week prior study entry Unwillingness terminate form psychotherapy Already receive adequate trial escitalopram CBT</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>